ONCOVITA
June 25, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
Oncovita, a biotechnology company spin-off from the Pasteur Institute, developing MVdeltaC, an engineered measles-based immuno-virotherapy designed to expose solid tumors so the immune system can recognize and destroy them.
MVdeltaC selectively infects CD46-rich tumor cells and activates a robust RIG-I driven immune response, driving cancer tumor cells into immunogenic death and revealing previously hidden tumor antigens. Built on the live attenuated measles vaccine, which has been safely administered to more than 4 billion people and has demonstrated safety in oncology settings, MVdeltaC converts cold, silent tumors into inflamed, immune-visible targets.
Our lead asset is at the pre-clinical stage of development, and we are currently raising €20M in two tranches to advance MVdeltaC into clinical development, with first-in-human studies targeted for mid-2027.
Company HQ City:
Paris
Company HQ State:
Ile de France
Company HQ Country:
France
Year Founded:
2015
Lead Product in Development:
MVdeltaC
CEO
Stéphane ALTABA
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
0
When you expect your next catalyst update?
CTA application: August 2027
What is your next catalyst (value inflection) update?
CTA/IND application
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}